

Summary of Studies Supporting USDA Product Licensure

Establishment Name	Ceva Animal Health, LLC					
USDA Vet Biologics Establishment Number	368					
Product Code	16L1.00					
True Name	Marek's Disease Vaccine, Serotype 1, Live Virus					
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Biomune Company CEVAC MD RISPENS - Biomune Company CEVAC MD RISPENS - CEVA Saude Animal Ltda. (Brazil) CEVAC MD RISPENS - No distributor specified					
Date of Compilation Summary	February 10, 2021					

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

Study Type	Efficacy					
Pertaining to	Marek's Disease Virus (MDV)					
Study Purpose	To demonstrate efficacy against MDV					
Product Administration	In ovo and subcutaneous route					
Study Animals	Chickens					
Challenge Description						
Interval observed after						
challenge						
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.					
USDA Approval Date	March 14, 2002					

Study Type	Efficacy					
Pertaining to	Marek's Disease Virus (MDV)					
Study Purpose	To demonstrate efficacy against MDV					
Product Administration	In ovo route and Subcutaneous route					
Study Animals	Chickens					
Challenge Description						
Interval observed after						
challenge						
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.					
USDA Approval Date	March 14, 2002					

Study Type	Safety									
Pertaining to	ALL									
Study Purpose	To demonstrate safety under field conditions									
Product	1. One dose administered via the <i>in ovo</i> route									
Administration	2. One dose administered via the subcutaneous (SQ) route									
Study Animals	1. Commercial chicken embryos at 18 to 19 days of incubation at									
v	three independent sites (<i>in ovo</i>)									
	2. Commercial chickens at day of age at three independent sites (SQ)									
Challenge	Not Applicable									
Description	11									
Interval observed	Animals w	Animals were observed daily for mortality through 21 days of age (in								
after challenge		<i>ovo</i> vaccination) and 21 days post vaccination (SQ vaccination).								
Results		/	2 1			/				
	Chickens v	Chickens were observed through 21 days of age								
	Location	Treatment Group	% Hatchability	Total Chicks Placed	% Mortality	Observations				
	1	In ovo Vaccinate	87.8	21,249	0.90	No adverse reactions				
	1	Control	87.7	17,071	0.98	No adverse reactions				
	2	In ovo Vaccinate	89.6	2,000	1.80	No adverse reactions				
		Control	88.5	2,000	1.95	No adverse reactions				
	2	In ovo Vaccinate	83.8	913	7.00	No adverse reactions				
	3	Control	83.2	1,132	9.45	No adverse reactions				
		SQ Vaccinate	Not Applicable	13,500	1.50	No adverse reactions				
	4	Control	Not Applicable	13,500	1.13	No adverse reactions				
		SQ Vaccinate	Not Applicable	9,000	1.07	No adverse reactions				
	5	Control	Not Applicable	13,000	1.61	No adverse reactions				
		SQ Vaccinate	Not Applicable	1,500	0.53	No adverse reactions				
	6	Control	Not Applicable	500	0.20	No adverse reactions				
USDA Approval Date	January 12	2, 2010								